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In the recent issue of Virulence, Ikram et al. have com-
piled an extensive proteomic bioinformatics study of
characteristic mutations in the hepatitis E virus (HEV)
genome. This study showed genotype-specific prevalence
of respective mutations and demonstrated the selective
pressure imposed upon the virus by both host immune
defense and antivirals.1
The evolutionary significance of virus infections has
been a subject of discussion for decades;2 however, mod-
ern omics-analyses (e.g., proteomics, transcriptomics)
and bioinformatics became crucial when it became
apparent that genetic variants of viruses were associated
to pathogenesis and disease progression. The first article
in terms of virus diversity and course of disease was pub-
lished by Pierre Lepine in 1938 who reported on the evo-
lution of different rabies virus strains and their
association to different characteristics of infectivity and
virulence.3 More recent reports have demonstrated the
significance of viral evolution in the pathogenesis of virus
infections, in particular of RNA viruses (HCV, HEV,
influenza virus) and HIV infections.4–8
Long thought to be a healthcare burden exclusive to
developing countries with sporadic cases in industrialized
countries confined to travel-borne infections, HEV is now
being increasingly recognized as an emerging disease glob-
ally.9 Reports of autochthonous cases of HEV infections
with zoonotically transmitted HEV genotypes 3 and 4 have
drastically increased in industrialized countries in the last
years.10,11 Although most cases remain asymptomatic or
present as acute self-limiting viral hepatitis, serious disease
outcomes may result in certain at-risk populations. Hepatic
failure and high mortality rates are common in HEV
patients with preexisting liver disease as well as infected
pregnant women.12,13 Chronic infections related to HEV
genotypes 3 and 4 can occur in immunocompromised per-
sons such as organ transplant recipients and HIV positive
patients.14,15 Beyond this, HEV may cause a wide spectrum
of extrahepatic manifestations.16 Off-label administration
of ribavirin monotherapy have shown to be effective in
cases of chronic infection, but their use has also laid bare
the ongoing struggle between the human immune system,
antiviral treatment, and HEV evolution.17,18
Viral adaptation as a response to host innate and
adaptive immune response and selective pressure by
antiviral treatment is critical to ensure continued viral
fitness and replication competency. Studies on chronic
infections with hepatitis B virus (HBV) and C virus
(HCV) are prime examples of how viral evolution can
overcome host immune defenses and antiviral therapy.
For example numerous immune-driven adaptations
within nonstructural regions of HCV have been
described, including genotype-specific HLA-associated
escape mutations.19,20 In addition, low efficacy of inter-
feron-based and nucleoside analogue therapy due to viral
heterogeneity and development of drug-resistant viral
quasispecies has been a common issue in treatment of
chronic HBV and HCV patients.21–23 These circumstan-
ces have long since underlined the necessity to better
understand the mechanisms involved in viral replication,
the functions of adaptive mutations, and to ultimately
develop more efficient treatment options, including
patient-tailored protocols and direct-acting antivirals.24
Unfortunately, we are far from having reached this
goal in the control of HEV. As a single-strand positive-
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sense RNA virus, HEV genome replication is extremely
error-prone since HEV RNA-dependent RNA polymer-
ase lacks proofreading activity and thus generates muta-
tions rapidly during transcription, undoubtedly
contributing to viral evolution. A plethora of mutations
within the three HEV open reading frames (ORFs) have
been described in vitro and in situ.8 However, those
described in patient-specific isolates may have the most
important impact on clinical application. Changes in the
HEV proteome are diverse and not well understood. Sev-
eral amino acid changes have been associated with
hepatic failure (e.g., F179S, C1483W, N1530T) and anti-
viral ribavirin therapy failure (G1634R/K) while larger
insertions into the hypervariable region (HVR) often
appear in the context of chronic hepatitis E.25–28
In light of the accumulating descriptions of patient-
specific HEV proteome alterations, there is an urgent
need to analyze their global prevalence and assess their
association to clinical outcomes. Undoubtedly, the opti-
mal antiviral treatment ensuring sustained virological
response is a personalized treatment strategy that targets
individual host and viral factors. Individualized therapy
could be optimized if treatment-naive viral quasispecies
and functional mutations have been identified and
assessed before treatment starts. This in turn requires a
comprehensive analysis of the true prevalence and signif-
icance of relevant mutations described so far.
In their article under discussion, Ikram and colleagues
employed elegant large-scale proteomic bioinformatics
to shed new light on previously described HEV muta-
tions associated with ribavirin treatment failure, chronic
infection, hepatic failure and altered immunoreactivity.
They carefully assessed the global prevalence of charac-
teristic mutations among different HEV genotypes
(HEV-1, HEV-3, and HEV-4), their impact on B an T
cell epitope reactivity and their genotype-specific evolu-
tion.1 The question posed by Ikram et al. at the onset of
their study was to identify which effects specific HEV
variants can have on susceptibility, pathogenesis of infec-
tion and treatment outcome.1 After exploring the Gen-
Bank and literature for clinical and in vitro data for
mutations in the HEV ORF1 and ORF2 regions the
investigators identified 20 characteristic amino acid var-
iants (17 in ORF1 and 3 in ORF2). In a next step they
assessed the prevalence of the 20 mutations within 406
full-length ORF1 and ORF2 sequences of different HEV
genotypes, while taking into account their association
with hepatic failure, treatment failure, chronicity and
altered immunoreactivity. The authors made the
astounding realization that specific mutations (9 out of
17 in ORF1, and 1 of 3 in ORF2) were conserved and by
contrast the remaining analyzed variations showed a
high degree of variability. The latter includes two notable
mutations T735I and G1634R/K that were frequent
among the major human pathogenic HEV genotypes 1,
3, and 4 and correlated with liver failure and ribavirin
therapy failure, respectively. Furthermore, two amino
acid residues Leu477 and Leu613 within the capsid pro-
tein (ORF2) known to be involved in formation of neu-
tralization-sensitive epitopes were mutated with
considerably high frequency in HEV genotype 1 and 3
implicating that immune evasion is a common strategy
in HEV infection.
Next, the investigators utilized in silico SNP algo-
rithms to predict whether the investigated mutations
were deleterious and caused protein destabilization,
respectively. Their finding indicates that most ORF1
mutations and 1 of 3 ORF2 mutations are indeed delete-
rious and that notably two ORF2 substitutions (P259S,
L477T) can destabilize the capsid protein structure.
The authors went on to investigate whether the
described mutations resulted in altered B and T cell epi-
tope antigenicity based on the hypothesis that acquisition
of escape mutations may hide the virus from host
defenses. Through a combination of epitope prediction
programs and online databases B and T cell epitopes
(class MHCI and MHCII) of HEV genotype 1, 3 and 4
consensus sequences were explored. Intriguingly, overlap
of epitopes and mutation sites were found for many of
the studied substitutions. Subsequent evaluation revealed
reduced antigenicity of mutated epitopes as compared to
wild-type with only few having retained or increased
antigenicity. These findings strongly imply that, similarly
to HBV and HCV, HEV may profit from altered epitopes
via decreased B and T cell recognition.
Finally, Ikram and colleagues mapped the evolution of
characteristic mutations for each HEV genotype. Nota-
bly, the investigators found that especially the mutations
T735I, the ribavirin failure-associated G1643R/K and
leucine substitutions L477T and L613T in ORF2 devel-
oped earlier in HEV genotype 1 than 3 and thus evolu-
tion of HEV-1 may have occurred earlier than HEV-3
and -4.
Taken together, Ikram and colleagues have addressed
an important issue of virus infection, namely virus evolu-
tion and the relevance of characteristic mutations in the
viral genome. The in-depth approach using large-scale
proteomic bioinformatics to characterize the intra-geno-
typic prevalence and evolution of HEV variants and their
implications for clinical outcomes and host immune eva-
sion is a prime example of how bioinformatics can be a
valuable tool to better understand the functions of viral
adaptation. As shown also for other viruses (e.g., HBV,
HCV, HIV, HCMV), the course of antiviral treatment
can be adjusted and optimized if host and viral factors
are assessed for each individual patient. The high
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mutation rate of HEV, the frequent emergence of ribavi-
rin failure-associated quasispecies and the ability of HEV
to hide from host immune defense are factors that
underline the necessity to profile and study characteristic
viral adaptations. There is therefore need to invest in
modern techniques since the powerful next generation
sequencing approaches (in-depth, whole genome etc.)
and digital epidemiology including intensified molecular
surveillance and proteomic bioinformatics will provide
us with the necessary tools to identify and discriminate
characteristic and relevant variations from polymor-
phisms in the viral genome. More detailed knowledge
about virus evolution and diversity will help us not only
to understand the pathophysiology of virus infection and
virus-host interactions but also to better manage infected
patients. Accordingly, the findings from Ikram and col-
leagues add new insights to our knowledge of the com-
plex processes of viral evolution, viral diversity, and
selection of HEV quasispecies. We are still at the early
stages of characterizing viral diversity and its association
with pathogenesis, immune defense, and therapy effi-
cacy. The paper under discussion is an excellent example
of how to explore virus diversity and its impact on the
course of infection using sophisticated methods. Only
then can the burden of serious hepatitis E be lifted.
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